Adaptin Bio opens Phase 1 brain cancer trial
Rhea-AI Filing Summary
ADAPTIN BIO, INC. (APTN) announced that enrollment has opened for a Phase 1, open-label, dose-escalation clinical trial of its proprietary BRiTE (Brain Bispecific T cell Engager) therapeutic APTN-101 as a treatment for EGFRvIII-positive glioblastoma, in collaboration with Duke University.
The study will enroll up to 15 adult patients with World Health Organization Grade IV Malignant Glioma. The primary objective is to evaluate the safety profile and maximum tolerated dose, with the primary endpoint being the proportion of patients with a dose limiting toxicity at each dose level. Secondary endpoints include pharmacokinetics and objective response rate, and exploratory endpoints include cytokine changes, anti-BRiTE antibodies, overall survival and progression free survival.
In preclinical models, APTN-101 increased brain distribution of an EGFRvIII T-cell engager by more than 7-fold and completely eradicated EGFRvIII glioblastoma tumors in 70%–80% of mice, while showing an excellent safety profile. The company highlights the significant unmet need in glioblastoma, where median survival is 12–18 months and about 5% of patients survive beyond five years.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Planned trial enrollment: Up to 15 adult patients
Preclinical brain distribution increase: Greater than 7-fold
Preclinical tumor eradication rate: 70%–80%
+5 more
8 metrics
Planned trial enrollment
Up to 15 adult patients
Phase 1 open-label, dose-escalation trial of APTN-101 in WHO Grade IV Malignant Glioma
Preclinical brain distribution increase
Greater than 7-fold
Increase in distribution of EGFRvIII T-cell engager into the brain with APTN-101 vs EGFRvIII T-cell engager alone
Preclinical tumor eradication rate
70%–80%
Complete eradication of EGFRvIII glioblastoma tumors in mice treated with APTN-101
Median survival in GBM
12–18 months
Median survival for patients diagnosed with glioblastoma under current standard-of-care therapies
Five-year survival in GBM
5%
Approximate proportion of glioblastoma patients surviving beyond five years
GBM treatment market size 2025
$3.02 billion
Estimated glioblastoma multiforme treatment market value in 2025
Projected GBM treatment market 2030
$4.44 billion
Forecast market value by 2030 with 8% CAGR
GBM new cases U.S.
Approximately 15,000 per year
Annual incidence of glioblastoma in the United States
Key Terms
Phase 1 clinical trial, dose limiting toxicity, pharmacokinetics, progression free survival, +2 more
6 terms
Phase 1 clinical trial medical
"enrollment has opened for a Phase 1 clinical trial evaluating its proprietary BRiTE"
A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.
dose limiting toxicity medical
"primary endpoint is the proportion of patients with a dose limiting toxicity"
Dose-limiting toxicity is a harmful side effect from a drug or treatment that becomes serious enough to prevent giving a higher dose; think of it as the safety limit that stops increasing the medicine’s amount. It matters to investors because that limit shapes how effective the drug can be, influences trial design, development costs and timelines, and can determine whether regulators approve the therapy or whether its commercial potential is reduced.
pharmacokinetics medical
"Secondary endpoints are the pharmacokinetics of APTN-101, and the objective response rate"
Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.
progression free survival medical
"Exploratory endpoints include an assessment of biological activity as evidenced by changes in cytokine levels, formation of anti-BRiTE antibodies, overall survival and progression free survival."
Progression free survival is the length of time during and after a treatment when a disease, such as cancer, does not get worse or spread. It is an important measure because longer periods of stability can indicate that a treatment is effectively controlling the condition. For investors, it provides insight into the potential durability and success of a therapy or medication.
blood-brain barrier medical
"designed to overcome the limitations for effective treatment of malignant brain tumors by enhancing the transport of therapies across the blood-brain barrier"
A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.
EGFRvIII medical
"GBM that expresses Epidermal Growth Factor Receptor variant III [EGFRvIII]"
FAQ
What did APTN announce in this Form 8-K filing?
APTN announced that enrollment has opened for a Phase 1, open-label, dose-escalation clinical trial of its BRiTE therapeutic APTN-101 for patients with EGFRvIII-positive glioblastoma, with Duke University as the study site for this first-in-human trial.
What is the design and goal of APTN-101’s Phase 1 trial for APTN?
The Phase 1 trial will enroll up to 15 adult patients and uses an open-label, dose-escalation design. Its primary objective is to evaluate the safety profile and determine the maximum tolerated dose, with the main endpoint being dose limiting toxicities at each dose level.
What preclinical results for APTN-101 does APTN highlight?
APTN reports that in preclinical studies APTN-101 produced a greater than 7-fold increase in brain distribution of the EGFRvIII T-cell engager and achieved complete eradication of EGFRvIII glioblastoma tumors in 70%–80% of mice, with an excellent safety profile and minimal off-target effects.
How severe is glioblastoma according to APTN’s disclosure?
Glioblastoma is described as one of the most aggressive and deadly brain cancers, with patients having a median survival of 12–18 months and only about 5% surviving beyond five years. It accounts for approximately 15,000 new cases per year in the U.S.
What market data for glioblastoma treatment does APTN provide?
APTN cites that the glioblastoma multiforme treatment market is valued at $3.02 billion in 2025 and is forecast to grow at an 8% CAGR to reach $4.44 billion by 2030, driven by demand for therapies that prolong survival.
What is BRiTE technology as described by APTN?
BRiTE is APTN’s proprietary Brain Bispecific T cell Engager technology, designed to enhance transport across the blood-brain barrier and selectively target EGFRvIII-expressing glioma cells. It leverages manipulated immune cells’ “hitchhiking” capabilities to deliver agents directly to brain tumors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
